NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients

Journal of Clinical Microbiology

Volumn 50, Issue 12, 2012, Pages 3886-3892

  El Shamy, Ahmed ^a,b,e   Shoji, Ikuo ^a   El Akel, Wafaa ^c   Bilasy, Shymaa E ^d   Deng, Lin ^a   El Raziky, Maissa ^c   Jiang, Da Peng ^a   Esmat, Gamal ^c   Hotta, Hak ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Suez Canal University   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

^d Suez Canal University   (Egypt)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORE PROTEIN; NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; EGYPT; FEMALE; GENE MUTATION; GENETIC HETEROGENEITY; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 4A; HUMAN; INTERFERON RIBAVIRIN RESISTANCE DETERMINING REGION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; EGYPT; GENETIC VARIATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MOLECULAR SEQUENCE DATA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RIBAVIRIN; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 4;

EID: 84869215141     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02109-12     Document Type: Article

References (41)

1. Abdel-Aziz F, et al. 2000. Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatology 32:111-115. (Pubitemid 30432374)
2. Abdel-Hamid M, et al. 2007. Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma. J. Gen. Virol. 88:1526-1531. (Pubitemid 46723235)
3. Akuta N, et al. 2009. Association of amino acid substitution pattern in core protein of hepatitisCvirus genotype 2a high viral load and virological response to interferon-ribavirin combination therapy. Intervirology 52:301-309.
4. Akuta N, et al. 2007. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J. Hepatol. 46:403-410. (Pubitemid 46185701)
5. Akuta N, et al. 2007. Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. Intervirology 50:361-368. (Pubitemid 350014920)
6. Akuta N, et al. 2005. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 48:372-380. (Pubitemid 41003622)
7. Amoroso P, et al. 1998. Correlation between virus genotype and chronicity rate in acute hepatitis C. J. Hepatol. 28:939-944. (Pubitemid 28275970)
8. Appel N, Pietschmann T, Bartenschlager R. 2005. Mutational analysis of hepatitis C virus nonstructural protein 5A: potential role of differential phosphorylation in RNA replication and identification of a genetically flexible domain. J. Virol. 79:3187-3194. (Pubitemid 40270599)
9. Asselah T, et al. 2012. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J. Hepatol. 56:527-532.
10. Chamberlain RW, Adams N, Saeed AA, Simmonds P, Elliott RM. 1997. Complete nucleotide sequence of a type 4 hepatitis C virus variant, the predominant genotype in the Middle East. J. Gen. Virol. 78(Pt 6):1341-1347. (Pubitemid 27281332)
11. De Nicola S, et al. 2012. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology 55:336-342.
12. El-Shamy A, et al. 2012. Polymorphisms of hepatitis C virus nonstructural protein 5A and core protein and clinical outcome of pegylatedinterferon/ ribavirin combination therapy. Intervirology 55:1-11.
13. El-Shamy A, et al. 2008. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ ribavirin combination therapy. Hepatology 48:38-47. (Pubitemid 351975529)
14. El-Shamy A, et al. 2007. Prediction of efficient virological response to pegylated interferon/ribavirin combination therapy by NS5A sequences of hepatitis C virus and anti-NS5A antibodies in pre-treatment sera. Microbiol. Immunol. 51:471-482. (Pubitemid 46641684)
15. El-Shamy A, et al. 2012. Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ ribavirin therapy. PLoS One 7:e30513. doi:10.1371/journal.pone.0030513.
16. El-Shamy A, et al. 2011. Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ ribavirin combination therapy. Microbiol. Immunol. 55:418-426.
17. el-Zayadi AR, et al. 2005. Hepatocellular carcinoma in Egypt: a single center study over a decade. World J. Gastroenterol. 11:5193-5198.
18. Enomoto N, et al. 1996. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N. Engl. J. Med. 334:77-81. (Pubitemid 26017933)
19. Fried MW, et al. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982.
20. Ge D, et al. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401.
21. Hassan MM, et al. 2001. The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients. J. Clin. Gastroenterol. 33:123-126. (Pubitemid 32685921)
22. Kau A, Vermehren J, Sarrazin C. 2008. Treatment predictors of a sustained virologic response in hepatitis B and C. J. Hepatol. 49:634-651.
23. Khattab MA, et al. 2011. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J. Hepatol. 54:1250-1262.
24. Limaye AR, Draganov PV, Cabrera R. 2011. Boceprevir for chronic HCV genotype 1 infection. N. Engl. J. Med. 365:176, 177-178.
25. Macdonald A, Harris M. 2004. Hepatitis C virus NS5A: tales of a promiscuous protein. J. Gen. Virol. 85:2485-2502. (Pubitemid 39214345)
26. Maekawa S, Enomoto N. 2009. Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C. J. Gastroenterol. 44:1009-1015.
27. Mattsson L, Sonnerborg A, Weiland O. 1993. Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. Liver 13:274-278. (Pubitemid 23307034)
28. Micallef JM, Kaldor JM, Dore GJ. 2006. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J. Viral Hepat. 13:34-41.
29. Moradpour D, et al. 2004. Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes. J. Virol. 78:7400-7409. (Pubitemid 38915885)
30. Murakami T, et al. 1999. Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection. Hepatology 30:1045-1053. (Pubitemid 29458295)
31. Okamoto H, et al. 1992. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J. Gen. Virol. 73(Pt 3):673-679.
32. Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. 2000. Genetic epidemiology of hepatitis C virus throughout Egypt. J. Infect. Dis. 182:698-707.
33. Sarasin-Filipowicz M. 2010. Interferon therapy of hepatitis C: molecular insights into success and failure. Swiss Med. Wkly. 140:3-11.
34. Sherman KE, et al. 2011. Response-guided telaprevir combination treatment for hepatitis C virus infection. N. Engl. J. Med. 365:1014-1024.
35. Simmonds P, et al. 2005. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42:962-973. (Pubitemid 41401136)
36. Simmonds P, et al. 1993. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J. Gen. Virol. 74(Pt 11):2391-2399. (Pubitemid 23332300)
37. Suppiah V, et al. 2009. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 41:1100-1104.
38. Tanaka E, Kiyosawa K. 2000. Natural history of acute hepatitis C. J. Gastroenterol. Hepatol. 15(Suppl):E97-E104. (Pubitemid 30435744)
39. Tanaka Y, et al. 2009. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41:1105-1109.
40. Timm J, et al. 2007. Characterization of full-length hepatitis C virus genotype 4 sequences. J. Viral Hepat. 14:330-337. (Pubitemid 46587848)
41. Yuan HJ, Jain M, Snow KK, Gale M, Jr, Lee WM. 2010. Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy. J. Viral Hepat. 17:208-216.